Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A epilepsy syndrome that occurs during childhood.
No HPO annotations are available for this condition.
Age of onset: childhood, at birth.
The clinical spectrum of GRIN2A-related disorders is broad and includes developmental delay/ intellectual disability (DD/ID), epilepsy, speech and language disorders, movement disorders, and neuropsychiatric disorders. Cognitive function can be normal or show mild-to-profound impairment. The spectrum of epilepsy phenotypes ranges from self-limited epilepsy with centrotemporal spikes (SeLECTS) to developmental and/or epileptic encephalopathies (DEE/EE) with spike-wave activation in sleep (DEE/EE-SWAS) – including Landau-Kleffner syndrome (LKS) – to infantile-onset DEE. Speech and language disorders range from mild speech impairment to aphasia to nonverbal phenotypes. Movement disorders occur less frequently and include ataxia, dystonia, and chorea.
A GRIN2A-related disorder should be considered in a proband with the following suggestive clinical findings and family history.
Clinical findings
Source: GeneReviews — "GRIN2A-Related Disorders"
No approved treatments are currently available for childhood-onset epilepsy syndrome. The disease remains an area of unmet medical need.
No clinical practice guidelines for GRIN2A-related disorders have been published.
To establish the extent of disease and needs in an individual diagnosed with GRIN2A-related disorders, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended.
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended.
Table 7.
GRIN2A-Related Disorders: Recommended Surveillance
System/Concern | Evaluation | Frequency
| Monitor developmental progress educational needs. | At each visit
No clinical trials have been registered for childhood-onset epilepsy syndrome.
15 publications have been identified in PubMed for childhood-onset epilepsy syndrome. Research spans Basic Science / Preclinical (33%), Clinical Trial Publication (20%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 5 | 33% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:07 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Source: GeneReviews — "GRIN2A-Related Disorders"
Genetic epilepsy syndromes. GRIN2A-related epilepsy phenotypes cannot be distinguished from other epilepsy-aphasia syndromes (EAS), apart from the ongoing subtle speech abnormalities that persist into adult life in those with GRIN2A pathogenic variants. GRIN2A-related infantile-onset developmental and epileptic encephalopathy (DEE) has no distinguishing features from other genetic causes. Note: While GRIN2A pathogenic variants can be associated with EAS, the majority of individuals with EAS do not have an identified genetic cause. A number of copy number variants (CNVs) have been associated with EAS in individual cases.
Source: GeneReviews — "GRIN2A-Related Disorders"
GRIN2A-Related Disorders: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Assessment of overall growth incl weight, height, head circumference |
| Developmental assessment | • To incl motor, adaptive, cognitive, speech-language eval
Evaluate for early intervention need for special education.
Assess for developmental regression across all areas.
| Neurologic eval | • EEG
Careful clinical history to identify seizures
In infancy childhood, sleep-deprived or sleep EEG w/monitoring to capture sleep, as this is essential to identify DEE-SWAS
| Consultation w/speech-language pathologist | Assessment for dyspraxia, dysarthria, language impairment
Movement disorders/
Musculoskeletal/
| Orthopedics/ physical medicine rehab/ PT OT eval | In severe DEE cases, consider eval for:
Gross motor fine motor skills;
Mobility, ADL, need for adaptive devices;
Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills).
Neurobehavioral/
| Neuropsychiatric eval | • Screening for behavior concerns incl sleep disturbances...
Source: GeneReviews — "GRIN2A-Related Disorders"
In individuals with GRIN2A-related disorders due to pathogenic missense variants activating the N-methyl-D-aspartate receptor (NMDAR), receptor-specific agonists and other activators (e.g., L-serine) should be avoided, as this could result in worsening of symptoms . In individuals with GRIN2A-related disorders due to pathogenic missense variants inhibiting the NMDAR as well as null variants, receptor-specific blockers should be used with caution (e.g., memantine, dextromethorphan, ketamine).
Source: GeneReviews — "GRIN2A-Related Disorders"
Several treatments are now under investigation in individuals with GRIN2A pathogenic gain-of-function (GOF) variants:
Source: GeneReviews — "GRIN2A-Related Disorders"
View trials for childhood-onset epilepsy syndrome
| • Assess for new manifestations such as seizures, changes in tone, movement disorders, regression
Assess for more subtle seizure types that many not have been recognized.
| Routine monitoring of speech language by speech-language pathologist should be considered, particularly in childhood. Parents should be asked by all clinicians about loss of understanding or regression in spoken language skills.
Neurobehavioral/
| Assess for behavioral disorders (particularly ADHD ASD) mental health issues (particularly anxiety, mood, psychotic disorders).
Musculoskeletal/
| Physical medicine (particularly in childhood), OT/PT assessment of mobility, self-help skills depending on childs phenotype
| Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning).
ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; OT = occupational therapy; PT = physical therapy
Source: GeneReviews — "GRIN2A-Related Disorders"
Clinical study results
3 |
20% |
Research summaries | 2 | 13% |
Patient case studies | 2 | 13% |
New treatment approaches | 2 | 13% |
Disease patterns and progression | 1 | 7% |
Lemke JR (2026). [PMID: 41087560](https://pubmed.ncbi.nlm.nih.gov/41087560/). *Molecular psychiatry*. [Gene Therapy / Novel Therapeutics]
Padilla H (2026). [PMID: 41621152](https://pubmed.ncbi.nlm.nih.gov/41621152/). *Epilepsy & behavior : E&B*. [Epidemiology / Natural History]
Singh S (2026). [PMID: 41270422](https://pubmed.ncbi.nlm.nih.gov/41270422/). *Seizure*. [Clinical Trial Publication]
Iasinovschi N (2026). [PMID: 41353983](https://pubmed.ncbi.nlm.nih.gov/41353983/). *Epilepsy research*. [Gene Therapy / Novel Therapeutics]
Zhang J (2026). [PMID: 42079822](https://pubmed.ncbi.nlm.nih.gov/42079822/). *Front Neurol*. [Basic Science / Preclinical]
Guerrini R (2025). [PMID: 40120618](https://pubmed.ncbi.nlm.nih.gov/40120618/). *The Lancet. Neurology*. [Review / Meta-Analysis]
Perez-Navarro VM (2025). [PMID: 40664003](https://pubmed.ncbi.nlm.nih.gov/40664003/). *Pediatric neurology*. [Review / Meta-Analysis]
Xu C (2025). [PMID: 40688221](https://pubmed.ncbi.nlm.nih.gov/40688221/). *Translational pediatrics*. [Case Report / Case Series]
Iasinovschi N (2025). [PMID: 41000990](https://pubmed.ncbi.nlm.nih.gov/41000990/). *bioRxiv : the preprint server for biology*. [Basic Science / Preclinical]
Ebrahim AK (2025). [PMID: 40727434](https://pubmed.ncbi.nlm.nih.gov/40727434/). *Case reports in pediatrics*. [Case Report / Case Series]